Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.

Tai CK, Wang W, Lai YH, Logg CR, Parker WB, Li YF, Hong JS, Sorscher EJ, Chen TC, Kasahara N.

Cancer Gene Ther. 2010 Sep;17(9):614-23. doi: 10.1038/cgt.2010.17. Epub 2010 May 14.

2.

In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.

Sorscher EJ, Hong JS, Allan PW, Waud WR, Parker WB.

Cancer Chemother Pharmacol. 2012 Aug;70(2):321-9. doi: 10.1007/s00280-012-1908-9. Epub 2012 Jul 4.

3.

Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts.

Kikuchi E, Menendez S, Ozu C, Ohori M, Cordon-Cardo C, Logg CR, Kasahara N, Bochner BH.

Cancer Gene Ther. 2007 Mar;14(3):279-86. Epub 2007 Jan 12.

PMID:
17218950
4.

Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene.

Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA, Moore BA, Bebok Z, Allan PW, Secrist JA 3rd, Parker WB, Sorscher EJ.

Cancer Res. 2004 Sep 15;64(18):6610-5.

5.

In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase.

Parker WB, King SA, Allan PW, Bennett LL Jr, Secrist JA 3rd, Montgomery JA, Gilbert KS, Waud WR, Wells AH, Gillespie GY, Sorscher EJ.

Hum Gene Ther. 1997 Sep 20;8(14):1637-44.

PMID:
9322865
6.

Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase.

Parker WB, Allan PW, Hassan AE, Secrist JA 3rd, Sorscher EJ, Waud WR.

Cancer Gene Ther. 2003 Jan;10(1):23-9.

PMID:
12489025
7.

Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy.

Xie X, Guo J, Kong Y, Xie GX, Li L, Lv N, Xiao X, Tang J, Wang X, Liu P, Yang M, Xie Z, Wei W, Spencer DM, Xie X.

J Gene Med. 2011 Dec;13(12):680-91. doi: 10.1002/jgm.1620. Erratum in: J Gene Med. 2012 Mar;14(3):217. Spencer, David M [added].

PMID:
22009763
8.

Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer.

Martiniello-Wilks R, Wang XY, Voeks DJ, Dane A, Shaw JM, Mortensen E, Both GW, Russell PJ.

J Gene Med. 2004 Dec;6(12):1343-57.

PMID:
15493036
9.

Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.

Parker WB, Allan PW, Waud WR, Hong JS, Sorscher EJ.

Cancer Gene Ther. 2011 Jun;18(6):390-8. doi: 10.1038/cgt.2011.4. Epub 2011 Mar 11.

11.

Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene.

Mohr L, Shankara S, Yoon SK, Krohne TU, Geissler M, Roberts B, Blum HE, Wands JR.

Hepatology. 2000 Mar;31(3):606-14.

PMID:
10706550
12.

Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.

Wang XY, Martiniello-Wilks R, Shaw JM, Ho T, Coulston N, Cooke-Yarborough C, Molloy PL, Cameron F, Moghaddam M, Lockett TJ, Webster LK, Smith IK, Both GW, Russell PJ.

Gene Ther. 2004 Nov;11(21):1559-67.

PMID:
15343359
13.

Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease.

Martiniello-Wilks R, Dane A, Voeks DJ, Jeyakumar G, Mortensen E, Shaw JM, Wang XY, Both GW, Russell PJ.

J Gene Med. 2004 Jan;6(1):43-54.

PMID:
14716676
14.

Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy.

Bharara S, Sorscher EJ, Gillespie GY, Lindsey JR, Hong JS, Curlee KV, Allan PW, Gadi VK, Alexander SA, Secrist JA 3rd, Parker WB, Waud WR.

Hum Gene Ther. 2005 Mar;16(3):339-47.

PMID:
15812229
15.

Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models.

Voeks D, Martiniello-Wilks R, Madden V, Smith K, Bennetts E, Both GW, Russell PJ.

Gene Ther. 2002 Jun;9(12):759-68.

16.

Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma.

Kawasaki Y, Tamamoto A, Takagi-Kimura M, Maeyama Y, Yamaoka N, Terada N, Okamura H, Kasahara N, Kubo S.

Cancer Gene Ther. 2011 Aug;18(8):571-8. doi: 10.1038/cgt.2011.25. Epub 2011 Jun 10.

17.

In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells.

Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ.

Gene Ther. 2000 Oct;7(20):1738-43.

18.
19.

Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine.

Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Johnston PB, Parker WB, Sorscher EJ, Cattaneo R.

Cancer Res. 2007 Nov 15;67(22):10939-47.

20.

Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.

Kikuchi E, Menendez S, Ozu C, Ohori M, Cordon-Cardo C, Logg CR, Kasahara N, Bochner BH.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4511-8.

Supplemental Content

Support Center